Form 4: KalVista Pharmaceuticals Executive Sells Shares to Cover Tax Obligations After Vesting

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, sold 7,192 shares to cover tax obligations following the vesting of restricted stock units and performance stock units.

Summary

• Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, engaged in transactions involving the company's stock.
• On November 17, 2024, Mr. Yea acquired 11,496 shares through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
• On November 18, 2024, Mr. Yea sold 7,192 shares at a weighted average price of $9.2565 per share.
• The sale was to cover tax withholding obligations related to the vesting of the RSUs and PSUs and was not a discretionary sale.
• Following these transactions, Mr. Yea directly owns 89,980 shares of KalVista Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when stock options or restricted stock units vest.

Comparison to Industry Standards

• The sale of shares to cover tax obligations is a standard practice among executives in publicly traded companies.
• Similar transactions are regularly reported by executives at comparable pharmaceutical companies.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally considered a normal part of executive compensation.

Key Dates

Keywords

KalVista Pharmaceuticals, insider trading, stock sale, restricted stock units, performance stock units, tax obligations, Christopher Yea, executive compensation